A ternary outcome for Tocagen
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Hard knocks for brain cancer, again
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
Upcoming events – crucial cancer data for Tocagen and Syndax
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.
Upcoming events – Tocagen’s brain cancer data and Restorbio tackles respiratory infections
Mid-stage data for Tocagen and Restorbio are approaching.
Biotech floats come back with a vengeance
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
